Free Trial

Merck & Co., Inc. (NYSE:MRK) Stock Price Up 2.2% - Here's Why

Merck & Co., Inc. logo with Medical background
Remove Ads

Shares of Merck & Co., Inc. (NYSE:MRK - Get Free Report) shot up 2.2% during trading on Friday . The company traded as high as $89.31 and last traded at $89.56. 2,766,673 shares changed hands during mid-day trading, a decline of 73% from the average session volume of 10,273,658 shares. The stock had previously closed at $87.60.

Wall Street Analyst Weigh In

Several brokerages have commented on MRK. Guggenheim cut their price target on shares of Merck & Co., Inc. from $122.00 to $115.00 and set a "buy" rating on the stock in a research report on Wednesday, February 12th. TD Securities downgraded Merck & Co., Inc. from a "buy" rating to a "hold" rating and lowered their target price for the company from $121.00 to $100.00 in a research report on Monday, February 10th. BMO Capital Markets reduced their price target on Merck & Co., Inc. from $105.00 to $96.00 and set a "market perform" rating for the company in a research report on Wednesday, February 5th. TD Cowen downgraded Merck & Co., Inc. from a "buy" rating to a "hold" rating and decreased their price target for the company from $121.00 to $100.00 in a research note on Monday, February 10th. Finally, Bank of America lowered their price target on Merck & Co., Inc. from $118.00 to $112.00 and set a "buy" rating on the stock in a research report on Wednesday, February 5th. Eleven investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, Merck & Co., Inc. currently has an average rating of "Moderate Buy" and an average target price of $117.12.

View Our Latest Stock Report on MRK

Remove Ads

Merck & Co., Inc. Trading Up 0.6 %

The business has a fifty day moving average price of $91.92 and a 200-day moving average price of $100.00. The company has a quick ratio of 1.15, a current ratio of 1.36 and a debt-to-equity ratio of 0.79. The company has a market cap of $226.69 billion, a P/E ratio of 13.33, a PEG ratio of 0.77 and a beta of 0.35.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The company reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.85 by ($0.13). Merck & Co., Inc. had a net margin of 26.67% and a return on equity of 45.35%. The firm had revenue of $15.62 billion during the quarter, compared to the consensus estimate of $15.51 billion. During the same quarter last year, the firm earned $0.03 earnings per share. The business's revenue for the quarter was up 6.8% compared to the same quarter last year. On average, analysts forecast that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, April 7th. Investors of record on Monday, March 17th will be paid a $0.81 dividend. The ex-dividend date of this dividend is Monday, March 17th. This represents a $3.24 annualized dividend and a dividend yield of 3.61%. Merck & Co., Inc.'s dividend payout ratio (DPR) is presently 48.14%.

Merck & Co., Inc. announced that its Board of Directors has authorized a stock repurchase program on Tuesday, January 28th that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the company to buy up to 4.1% of its stock through open market purchases. Stock repurchase programs are often a sign that the company's leadership believes its shares are undervalued.

Insider Buying and Selling at Merck & Co., Inc.

In related news, Director Inge G. Thulin acquired 2,833 shares of the company's stock in a transaction on Thursday, February 6th. The stock was purchased at an average cost of $88.25 per share, with a total value of $250,012.25. Following the acquisition, the director now directly owns 2,933 shares of the company's stock, valued at approximately $258,837.25. The trade was a 2,833.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Cristal N. Downing sold 2,361 shares of the company's stock in a transaction on Thursday, February 6th. The shares were sold at an average price of $88.76, for a total value of $209,562.36. Following the sale, the insider now owns 7,085 shares of the company's stock, valued at approximately $628,864.60. The trade was a 24.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.09% of the company's stock.

Hedge Funds Weigh In On Merck & Co., Inc.

Hedge funds have recently bought and sold shares of the company. Mascagni Wealth Management Inc. acquired a new stake in shares of Merck & Co., Inc. during the 4th quarter worth approximately $76,000. Chancellor Financial Group WB LP acquired a new position in Merck & Co., Inc. during the 4th quarter worth approximately $561,000. 111 Capital bought a new position in Merck & Co., Inc. in the 4th quarter valued at approximately $874,000. Wealth Enhancement Advisory Services LLC boosted its position in Merck & Co., Inc. by 17.5% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 1,560,491 shares of the company's stock valued at $155,238,000 after buying an additional 231,927 shares in the last quarter. Finally, NorthCrest Asset Manangement LLC boosted its position in Merck & Co., Inc. by 3.8% in the fourth quarter. NorthCrest Asset Manangement LLC now owns 141,377 shares of the company's stock valued at $14,064,000 after buying an additional 5,150 shares in the last quarter. 76.07% of the stock is owned by institutional investors.

Merck & Co., Inc. Company Profile

(Get Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Recommended Stories

Should You Invest $1,000 in Merck & Co., Inc. Right Now?

Before you consider Merck & Co., Inc., you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.

While Merck & Co., Inc. currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Trump Tariffs Tumble the Stock Market—Here’s How to Protect Your Money
Donald Trump Owns These 7 Stocks, Should You?
 5 Stocks to BUY NOW in April 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads